{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:06:44Z","timestamp":1771830404397,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Congenital hemophilia A is a recessive inherited hemorrhagic disorder caused by factor VIII (FVIII) deficiency. According to the activity of functional coagulation FVIII, the severity of hemophilia A is divided into three levels: mild, moderate and severe. The characteristic phenotype in hemophilia is the bleeding tendency. Clinical severity depends on the extent of the FVIII deficiency and the first bleeding episode in severe and moderate congenital hemophilia A usually occurs in early childhood. At present, there are few reports on symptomatic severe congenital hemophilia A in the neonatal period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We describe a pair of monozygotic twin brothers with severe hemophilia A. Patient-related factors, including a birth weight discrepancy of 10%, the need for non-invasive respiratory support due to mild respiratory distress, duration of breastfeeding, and vaccinations, were similar in both twins. Anti-hemorrhagic prophylaxis was carried out after birth with IM vitamin K. Due to the presence of prolonged bleeding at the sampling site after performing EGA (Blood Gas Analysis) and neonatal screening, a coagulation test was carried out and a coagulation factor assay (dosage of activity of factors VII, IX, XI, XII) was performed accordingly: activated partial thromboplastin time (APTT) was prolonged without extended prothrombin time (PT). Factor VIII activity was completely absent (0.7%) in both twins. Hematological consultancy was requested and a diagnosis of severe congenital hemophilia A was established. Emicizumab was started as the primary anti-hemorrhagic prophylaxis, with good response and no major bleeding events in the first year of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The coagulation system is not fully developed at birth, complicating clinical decision-making and the correct interpretation of coagulation testing. Targeted coagulation profiling and factor assays are mission-critical for newborns from twin pregnancies when a hematological disorder is suspected. Coagulation factor assays are essential to confirm the diagnosis of hemophilia A. An early diagnosis of hemophilia is crucial for the timely initiation of an appropriate management plan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1770910","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:35Z","timestamp":1771828235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Monochorionic diamniotic twin brothers with severe hemophilia A: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Lorenzo","family":"Riboldi","sequence":"first","affiliation":[{"name":"Neonatal Unit, Department of Public Health and Pediatric Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Coscia","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Department of Public Health and Pediatric Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Peila","sequence":"additional","affiliation":[{"name":"Neonatal Unit, Department of Public Health and Pediatric Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2516.2010.02309_1.x","article-title":"Haemophilic arthropathy","volume":"16","author":"Llina\u2019s","year":"2010","journal-title":"Haemophilia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood.V86.6.2206.bloodjournal8662206","article-title":"Factor VIII gene inversions in severe hemophilia A: results of an international consortium study","volume":"86","author":"Antonarakis","year":"1995","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1111\/j.1538-7836.2006.02105.x","article-title":"Female hemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII","volume":"4","author":"Cai","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Association of hemophilia clinic directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/hae.14412","article-title":"Prophylaxis in children with haemophilia in an evolving treatment landscape","volume":"27","author":"Mancuso","year":"2021","journal-title":"Haemophilia"},{"key":"B7","year":""},{"key":"B8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/hae.12470","article-title":"Similar bleeding phenotype in young children with haemophilia A or B: a cohort study","volume":"20","author":"Clausen","year":"2014","journal-title":"Haemophilia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/hae.13075","article-title":"Non-genetic risk factors in haemophilia A inhibitor management\u2014the danger theory and the use of animal models","volume":"22","author":"Lovgren","year":"2016","journal-title":"Haemophilia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"10","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.18553\/jmcp.2020.19318","article-title":"Comparing factor use and bleed rates in U.S. hemophilia A patients receiving prophylaxis with 3 different long-acting recombinant factor VIII products","volume":"26","author":"Simpson","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-2516.2003.00704.x","article-title":"Female haemophiliac homozygous for the factor VIII intron 22 inversion mutation, with transcriptional inactivation of one of the factor VIII alleles","volume":"9","author":"David","year":"2003","journal-title":"Haemophilia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/blood-2002-01-0277","article-title":"Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A","volume":"100","author":"Valleix","year":"2002","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ajh.21219","article-title":"Female monozygotic twins discordant for hemophilia A due to nonrandom X-chromosome inactivation","volume":"83","author":"Bennett","year":"2008","journal-title":"Am J Hematol"},{"key":"B15","volume-title":"Canadian Comprehensive Care Standards for Hemophilia and Other Inherited Bleeding Disorders","year":"2007"},{"key":"B16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1160\/th15-03-0212","article-title":"The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors","volume":"115","author":"van Velzen","year":"2016","journal-title":"Thromb Haemost"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s40265-016-0622-z","article-title":"Efmoroctocog alfa: a review in haemophilia A","volume":"76","author":"Frampton","year":"2016","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1111\/bjh.16740","article-title":"Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia","volume":"190","author":"Andersson","year":"2020","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1182\/blood.2021011849","article-title":"Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis","volume":"138","author":"Zwagemaker","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/uog.27583","article-title":"Fetal and neonatal neuroimaging in twin\u2013twin transfusion syndrome","volume":"63","author":"Spruijt","year":"2024","journal-title":"Ultrasound Obstet Gynecol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"B22","author":"Keeney","year":"2010"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1016\/j.jtha.2024.08.017","article-title":"Estimation of gestational age-specific reference intervals for coagulation assays in a neonatal intensive care unit using real-world data","volume":"22","author":"Lalos","year":"2024","journal-title":"J Thromb Haemost"},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/cclm-2021-0967","article-title":"Coagulation parameters in the newborn and infant\u2014the Copenhagen Baby Heart and COMPARE studies","volume":"60","author":"Nielsen","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/blood.V70.1.165.165","article-title":"Development of the human coagulation system in the full-term infant","volume":"70","author":"Andrew","year":"1987","journal-title":"Blood"},{"key":"B26","first-page":"S112","article-title":"Current challenges in the management of hemophilia","volume":"21","author":"Bauer","year":"2015","journal-title":"Am J Manag Care"},{"key":"B27","volume-title":"Guide for the Assessment of Clotting Factor Concentrates","author":"Farrugia","year":"2008"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/jth.13298","article-title":"When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH","volume":"14","author":"Fischer","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1351-8216.2001.00134.x","article-title":"Inhibitor development in correlation to factor VIII genotypes","volume":"8","author":"Oldenburg","year":"2002","journal-title":"Haemophilia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Eng J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Eng J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmaco-kinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicenter, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1770910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:30:37Z","timestamp":1771828237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1770910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":36,"alternative-id":["10.3389\/fped.2026.1770910"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1770910","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1770910"}}